Perspective announces first patient dosed in Phase 1/2a study of VMT-a-NET

Perspective Therapeutics announced that the first patient was dosed at Washington University in St Louis in the Company’s Phase 1/2a trial evaluating the safety and efficacy of (212Pb)VMT-alpha-NET, a targeted alpha-particle therapy, in patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors. The trial is a multi-center, open-label dose escalation, dose expansion study of VMT-alpha-NET in patients who have not received prior peptide receptor radionuclide therapy. “We are proud of our team’s commitment and progress in bringing our radionuclide therapy to patients suffering from these difficult-to-treat neuroendocrine tumors,” said Thijs Spoor, Chief Executive Officer of Perspective Therapeutics. “Based on the promising clinical data observed in the investigator-led study in India that was presented at the recent European Association of Nuclear Medicine meeting, we believe VMT-alpha-NET has the potential to provide significant improvements in clinical outcomes compared to standard of careDOTATATE. With our FDA Fast Track Designation for first-line treatment in all neuroendocrine tumors, we plan to rapidly advance this product through clinical development.”